Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$2190.00
-50.00 (-2.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $992.1M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$25.5B
P/E
33.7x
↑EV/EBITDA
8.5x
↓ROE
1.8%
↑Gross Margin
60.4%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
—
FCF margin
1.9%
FCF / Net income
1.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $52.15B · net income $753.6M · FCF $992.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.15B | $52.15B | $53.58B | $52.46B | $50.06B |
| Net Income | $753.6M | $753.6M | $1.70B | $3.52B | $855.1M |
| EBITDA | $3.87B | $3.87B | $4.69B | $6.41B | $2.62B |
| EPS | 65.00 | 65.00 | 146.00 | 302.00 | 95.00 |
| Gross Margin | 60.4% | 60.4% | 61.5% | 60.2% | 64.2% |
| Operating Margin | -2.5% | -2.5% | 2.9% | 2.3% | 3.5% |
| Net Margin | 1.4% | 1.4% | 3.2% | 6.7% | 1.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.40 | 0.28 | 0.42 |
| Current Ratio | 2.38 | 2.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $992.1M | $992.1M | $-5.24B | $3.37B | $-1.38B |
| Returns | |||||
| ROE | 1.8% | 1.8% | 4.2% | 9.1% | 2.4% |
| Valuation | |||||
| P/E | 33.69 | 33.69 | 23.56 | 12.58 | 53.47 |
| EV/EBITDA | 8.48 | 8.48 | 10.36 | 7.58 | 18.70 |
| P/B | 0.62 | 0.62 | 1.00 | 1.15 | 1.29 |
| Growth & Yield | |||||
| Revenue Growth | -2.7% | -2.7% | 2.1% | 4.8% | — |
| EPS Growth | -55.5% | -55.5% | -51.7% | 217.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
44.1%
EPS terminal req.
$194.33
Spread vs growth
-99.5%
5Y implied EPS CAGR
29.3%
EPS terminal req.
$235.13
Spread vs growth
-84.8%
10Y implied EPS CAGR
19.3%
EPS terminal req.
$378.69
Spread vs growth
-74.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.6%
Start / end P/E
22.6x → 33.7x
EPS bridge
146.00 → 65.00
Residual
-27.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.